Olga Kordonouri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Olga Kordonouri has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
T. Danne
4 shared publicationsR. Hartmann
2 shared publicationsA Grüters-Kieslich
1 shared publicationA. Dorow
Clinics for General Paediatrics and
1 shared publicationA. Grüters‐Kieslich
Clinics for General Paediatrics and
1 shared publicationAlbrecht Klinghammer
Klinikum Chemnitz GmbH, Children’s Hospital, Chemnitz, Germany
1 shared publication
Latest Publications
- 1 June 2008
- Vol. 31 (6) , 200
[Type 1 diabetes in children and adolescents--new strategies in management and treatment].
Type 1 diabetes (T1D) is the most common metabolic disease in childhood with an increasing incidence of about 3 to 5% per year, particularly in preschool children. Despite substantial progresses in diabetes research concerning its pathogenesis and etiology in the last decades, there is no strategy for primary prevention in subjects with subclinical signs of diabetes. Nowadays, it is well-known that T1D is caused by partial or total destruction of pancreatic islet cells, resulting in progressive incapacity to produce insulin. This inflammation is of an autoimmune nature, resulting both from environmental and genetic influences. Children with T1D usually have a several day history of typical symptoms such as frequent urination, excessive thirst and weight loss, which appear when about 80% of the pancreatic beta cells are already destroyed. If those symptoms are misinterpreted, the continuing hyperglycaemic metabolism leads to a potential life-threatening condition the diabetic ketoacidosis. Patients with T1D require daily subcutaneous injections of insulin, with the overall aim to mimic the physiological release of insulin during meal-associated and fasting periods (intensive insulin therapy). The most important parameters to evaluate the effectiveness of insulin treatment are blood glucose monitoring and HbA1c. The increased availability of systems for continuous glucose monitoring may help patients to have a better insight into their metabolic conditions. Sensor-based insulin treatment is likely to have a significant impact on paediatric diabetes therapy and education in the future.
- 1 June 2008
- Vol. 31 (6) , 200
[Type 1 diabetes in children and adolescents--new strategies in management and treatment].
Type 1 diabetes (T1D) is the most common metabolic disease in childhood with an increasing incidence of about 3 to 5% per year, particularly in preschool children. Despite substantial progresses in diabetes research concerning its pathogenesis and etiology in the last decades, there is no strategy for primary prevention in subjects with subclinical signs of diabetes. Nowadays, it is well-known that T1D is caused by partial or total destruction of pancreatic islet cells, resulting in progressive incapacity to produce insulin. This inflammation is of an autoimmune nature, resulting both from environmental and genetic influences. Children with T1D usually have a several day history of typical symptoms such as frequent urination, excessive thirst and weight loss, which appear when about 80% of the pancreatic beta cells are already destroyed. If those symptoms are misinterpreted, the continuing hyperglycaemic metabolism leads to a potential life-threatening condition the diabetic ketoacidosis. Patients with T1D require daily subcutaneous injections of insulin, with the overall aim to mimic the physiological release of insulin during meal-associated and fasting periods (intensive insulin therapy). The most important parameters to evaluate the effectiveness of insulin treatment are blood glucose monitoring and HbA1c. The increased availability of systems for continuous glucose monitoring may help patients to have a better insight into their metabolic conditions. Sensor-based insulin treatment is likely to have a significant impact on paediatric diabetes therapy and education in the future.
- Open Access
- 1 April 2005
- Published by BMJ in Archives of Disease in Childhood
- Vol. 90 (4) , 411-414
Natural course of autoimmune thyroiditis in type 1 diabetes: association with gender, age, diabetes duration, and puberty
Aims: To investigate the natural history and incidence of autoimmune thyroiditis (AIT) in paediatric patients with type 1 diabetes (T1D). Methods: Since 1990, annual screening for thyroid disease has been performed in children and adolescents with T1D. Antibodies against thyroperoxidase (anti-TPO) and thyroglobulin (anti-TG) as well as TSH were measured in 659 patients (54.3% boys). In 126 patients, anti-TPO and anti-TG levels were followed at yearly intervals from onset up to five years of T1D. Anti-TPO above 30 U/ml and anti-TG above 20 U/ml were considered positive, values above 100 U/ml as significantly raised and indicative of AIT. L-thyroxine treatment was started if TSH was higher than 4.5 μU/ml and/or thyroid gland enlargement on thyroid ultrasound was present. Results: At initial screening, 15.4% of patients had raised anti-TPO and 14.4% anti-TG. Girls had more frequently raised antibodies than boys. Sixty two patients (9.4%, 61% girls) required treatment with L-thyroxine. The cumulative incidence (SE) of AIT after 10 years of diabetes was 0.14 (0.02), being significantly higher in females (0.18 (0.03)), particularly after the age of 12 years. At T1D onset, positive anti-TPO and anti-TG were present in 21 of 126 patients (16.7%), each. All patients with significantly increased values of anti-TPO (n = 17, 148–5340 U/ml) and anti-TG (n = 11, 140–2000 U/ml) at T1D onset remained positive during the following five years. Conclusions: For early detection of autoimmune thyroiditis in children with T1D, measurement of anti-TPO and TSH at T1D onset and in yearly intervals after the age of 12 years is recommended.
- 1 April 2005
- Published by BMJ in Archives of Disease in Childhood
- Vol. 90 (4) , 411-414
Open AccessNatural course of autoimmune thyroiditis in type 1 diabetes: association with gender, age, diabetes duration, and puberty
Aims: To investigate the natural history and incidence of autoimmune thyroiditis (AIT) in paediatric patients with type 1 diabetes (T1D). Methods: Since 1990, annual screening for thyroid disease has been performed in children and adolescents with T1D. Antibodies against thyroperoxidase (anti-TPO) and thyroglobulin (anti-TG) as well as TSH were measured in 659 patients (54.3% boys). In 126 patients, anti-TPO and anti-TG levels were followed at yearly intervals from onset up to five years of T1D. Anti-TPO above 30 U/ml and anti-TG above 20 U/ml were considered positive, values above 100 U/ml as significantly raised and indicative of AIT. L-thyroxine treatment was started if TSH was higher than 4.5 μU/ml and/or thyroid gland enlargement on thyroid ultrasound was present. Results: At initial screening, 15.4% of patients had raised anti-TPO and 14.4% anti-TG. Girls had more frequently raised antibodies than boys. Sixty two patients (9.4%, 61% girls) required treatment with L-thyroxine. The cumulative incidence (SE) of AIT after 10 years of diabetes was 0.14 (0.02), being significantly higher in females (0.18 (0.03)), particularly after the age of 12 years. At T1D onset, positive anti-TPO and anti-TG were present in 21 of 126 patients (16.7%), each. All patients with significantly increased values of anti-TPO (n = 17, 148–5340 U/ml) and anti-TG (n = 11, 140–2000 U/ml) at T1D onset remained positive during the following five years. Conclusions: For early detection of autoimmune thyroiditis in children with T1D, measurement of anti-TPO and TSH at T1D onset and in yearly intervals after the age of 12 years is recommended.
- 1 May 2004
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 129 (20) , 1145-1148
Diabetes-assoziierte Autoimmunerkrankungen bei Kindern und Jugendlichen: Wie sinnvoll ist eine Früherkennung?
Autoimmun-Erkrankungen wie Zöliakie und Autoimmun-Thyreoiditis treten überproportional häufig bei Patienten mit Typ 1-Diabetes auf. Da diese Erkrankungen oft ohne eindeutige klinische Symptomatik verlaufen, kann ihre Früherkennung nur durch die serologische Bestimmung der spezifischen Autoantikörper erfolgen. In der Literatur wird die Prävalenz einer durch Screening-Verfahren entdeckten Zöliakie oder Autoimmun-Thyreoiditis bei jungen Patienten mit Typ 1-Diabetes im Mittel 10-mal höher angegeben als für die Normalbevölkerung. Bislang gibt es jedoch keine Einigkeit über ein einheitliches Vorgehen zum Screening und für die Indikation einer Behandlung bei klinisch nicht auffälligen Patienten mit serologisch nachweisbarer Autoimmunität. Zu spät erkannte Begleiterkrankungen können aber zu klinisch relevanten Stoffwechselproblemen und weiteren vermeidbaren Komplikationen führen. Coeliac disease (CD) and autoimmune thyreoiditis (AIT) are associated with type-1 diabetes. These diseases frequently occur without apparent clinical symptoms. Therefore, a serological screening by autoantibody testing is required for early detection. Identified by screening, the prevalence of CD and AIT is reported to be up to 10-fold higher in young patients with type-1 diabetes than in healthy children. Up to now, no uniform recommendations exist regarding a standardized screening procedure as well as the treatment of patients with clinically asymptomatic disorder and evidence of autoimmunity. A delay in the detection of associated diseases, however, may lead to clinical relevant, but otherwise preventable complications.
- 1 May 2004
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 129 (20) , 1145-1148
Diabetes-assoziierte Autoimmunerkrankungen bei Kindern und Jugendlichen: Wie sinnvoll ist eine Früherkennung?
Autoimmun-Erkrankungen wie Zöliakie und Autoimmun-Thyreoiditis treten überproportional häufig bei Patienten mit Typ 1-Diabetes auf. Da diese Erkrankungen oft ohne eindeutige klinische Symptomatik verlaufen, kann ihre Früherkennung nur durch die serologische Bestimmung der spezifischen Autoantikörper erfolgen. In der Literatur wird die Prävalenz einer durch Screening-Verfahren entdeckten Zöliakie oder Autoimmun-Thyreoiditis bei jungen Patienten mit Typ 1-Diabetes im Mittel 10-mal höher angegeben als für die Normalbevölkerung. Bislang gibt es jedoch keine Einigkeit über ein einheitliches Vorgehen zum Screening und für die Indikation einer Behandlung bei klinisch nicht auffälligen Patienten mit serologisch nachweisbarer Autoimmunität. Zu spät erkannte Begleiterkrankungen können aber zu klinisch relevanten Stoffwechselproblemen und weiteren vermeidbaren Komplikationen führen. Coeliac disease (CD) and autoimmune thyreoiditis (AIT) are associated with type-1 diabetes. These diseases frequently occur without apparent clinical symptoms. Therefore, a serological screening by autoantibody testing is required for early detection. Identified by screening, the prevalence of CD and AIT is reported to be up to 10-fold higher in young patients with type-1 diabetes than in healthy children. Up to now, no uniform recommendations exist regarding a standardized screening procedure as well as the treatment of patients with clinically asymptomatic disorder and evidence of autoimmunity. A delay in the detection of associated diseases, however, may lead to clinical relevant, but otherwise preventable complications.
- 1 January 2004
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 17 (7) , 975-982
Prevalence of 20S Proteasome, Anti-nuclear and Thyroid Antibodies in Young Patients at Onset of Type 1 Diabetes Mellitus and the Risk of Autoimmune Thyroiditis
Patients with type 1 diabetes mellitus (DM1) are at high risk to develop further autoimmune disorders, which are mostly characterized by the presence of organ-specific antibodies in serum and a subclinical disease course. Diabetes-related (glutamic acid decarboxylase, tyrosine phosphatase, IA-2) and thyroid-specific (thyroperoxidase, thyroglobulin) as well as antibodies to 20S proteasome, and anti-nuclear antibodies, were measured at DM1 onset in 147 children and adolescents. Patients were followed prospectively for the development of autoimmune thyroiditis (TSH elevation and/or sonographic thyroid gland enlargement in the presence of thyroid antibodies) up to 12 years, median observation time 4.4 years. Eight of 147 (5.4%) patients developed autoimmune thyroiditis. The cumulative incidence (+/-SE) at 5 years was 0.08+/-0.03. The prevalence of thyroid antibodies was 16.7%, of DM-related 88.4%, 20S proteasome 21.9%, and anti-nuclear antibodies 20.0%. There was a positive correlation between thyroid and anti-nuclear antibodies (p <0.001). Clinical course of DM1 and remission duration were not influenced by the presence of autoantibodies. However, in contrast to patients without antibodies, those with positive antibodies had significantly (p <0.001) elevated cumulative incidence of autoimmune thyroiditis at 5 years: thyroperoxidase 0.40+/-0.13, thyroglobulin 0.38+/-0.15, and anti-nuclear antibodies 0.29+/-0.12, respectively. These data underline that autoimmunity in patients with DM1 is not only restricted to beta-cell antigens at the onset of disease. In particular, patients with positive thyroid and anti-nuclear antibodies are at high risk to develop autoimmune thyroiditis during the first 5 years of DM1.
- 1 January 2004
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 17 (7) , 975-982
Prevalence of 20S Proteasome, Anti-nuclear and Thyroid Antibodies in Young Patients at Onset of Type 1 Diabetes Mellitus and the Risk of Autoimmune Thyroiditis
Patients with type 1 diabetes mellitus (DM1) are at high risk to develop further autoimmune disorders, which are mostly characterized by the presence of organ-specific antibodies in serum and a subclinical disease course. Diabetes-related (glutamic acid decarboxylase, tyrosine phosphatase, IA-2) and thyroid-specific (thyroperoxidase, thyroglobulin) as well as antibodies to 20S proteasome, and anti-nuclear antibodies, were measured at DM1 onset in 147 children and adolescents. Patients were followed prospectively for the development of autoimmune thyroiditis (TSH elevation and/or sonographic thyroid gland enlargement in the presence of thyroid antibodies) up to 12 years, median observation time 4.4 years. Eight of 147 (5.4%) patients developed autoimmune thyroiditis. The cumulative incidence (+/-SE) at 5 years was 0.08+/-0.03. The prevalence of thyroid antibodies was 16.7%, of DM-related 88.4%, 20S proteasome 21.9%, and anti-nuclear antibodies 20.0%. There was a positive correlation between thyroid and anti-nuclear antibodies (p <0.001). Clinical course of DM1 and remission duration were not influenced by the presence of autoantibodies. However, in contrast to patients without antibodies, those with positive antibodies had significantly (p <0.001) elevated cumulative incidence of autoimmune thyroiditis at 5 years: thyroperoxidase 0.40+/-0.13, thyroglobulin 0.38+/-0.15, and anti-nuclear antibodies 0.29+/-0.12, respectively. These data underline that autoimmunity in patients with DM1 is not only restricted to beta-cell antigens at the onset of disease. In particular, patients with positive thyroid and anti-nuclear antibodies are at high risk to develop autoimmune thyroiditis during the first 5 years of DM1.
- 1 August 2002
- Published by American Diabetes Association in Diabetes Care
- Vol. 25 (8) , 1346-1350
Thyroid Autoimmunity in Children and Adolescents With Type 1 Diabetes
OBJECTIVE—To investigate thyroid autoimmunity in a very large nationwide cohort of children and adolescents with type 1 diabetes. RESEARCH DESIGN AND METHODS—Data were analyzed from 17,749 patients with type 1 diabetes aged 0.1–20 years who were treated in 118 pediatric diabetes centers in Germany and Austria. Antibodies to thyroglobulin (anti-TG) and thyroperoxidase (anti-TPO) were measured and documented at least once in 7,097 patients. A total of 49.5% of these patients were boys, the mean age was 12.4 years (range 0.3–20.0 years), and the mean duration of diabetes was 4.5 years (range 0.0–19.5 years). A titer exceeding 100 units/ml or 1:100 was considered significantly elevated. RESULTS—In 1,530 patients, thyroid antibody levels were elevated on at least one occasion, whereas 5,567 were antibody-negative during the observation period. Patients with thyroid antibodies were significantly older (P < 0.001), had a longer duration of diabetes (P < 0.001), and developed diabetes later in life (P < 0.001) than those without antibodies. A total of 63% of patients with positive antibodies were girls, compared with 45% of patients without antibodies (P < 0.001). The prevalence of significant thyroid antibody titers increased with increasing age; the highest prevalence was in the 15- to 20-year age group (anti-TPO: 16.9%, P < 0.001; anti-TG: 12.8%, P < 0.001). Thyroid-stimulating hormone (TSH) levels were higher in patients with thyroid autoimmunity (3.34 μU/ml, range 0.0–615.0 μU/ml) than in control subjects (1.84 μU/ml, range 0.0–149.0 μU/ml) (P < 0.001). Even higher TSH levels were observed in patients with both anti-TPO and anti-TG (4.55 μU/ml, range 0.0–197.0 μU/ml). CONCLUSIONS—Thyroid autoimmunity seems to be particularly common in girls with diabetes during the second decade of life and may be associated with elevated TSH levels, indicating subclinical hypothyroidism.
- 1 August 2002
- Published by American Diabetes Association in Diabetes Care
- Vol. 25 (8) , 1346-1350
Thyroid Autoimmunity in Children and Adolescents With Type 1 Diabetes
OBJECTIVE—To investigate thyroid autoimmunity in a very large nationwide cohort of children and adolescents with type 1 diabetes. RESEARCH DESIGN AND METHODS—Data were analyzed from 17,749 patients with type 1 diabetes aged 0.1–20 years who were treated in 118 pediatric diabetes centers in Germany and Austria. Antibodies to thyroglobulin (anti-TG) and thyroperoxidase (anti-TPO) were measured and documented at least once in 7,097 patients. A total of 49.5% of these patients were boys, the mean age was 12.4 years (range 0.3–20.0 years), and the mean duration of diabetes was 4.5 years (range 0.0–19.5 years). A titer exceeding 100 units/ml or 1:100 was considered significantly elevated. RESULTS—In 1,530 patients, thyroid antibody levels were elevated on at least one occasion, whereas 5,567 were antibody-negative during the observation period. Patients with thyroid antibodies were significantly older (P < 0.001), had a longer duration of diabetes (P < 0.001), and developed diabetes later in life (P < 0.001) than those without antibodies. A total of 63% of patients with positive antibodies were girls, compared with 45% of patients without antibodies (P < 0.001). The prevalence of significant thyroid antibody titers increased with increasing age; the highest prevalence was in the 15- to 20-year age group (anti-TPO: 16.9%, P < 0.001; anti-TG: 12.8%, P < 0.001). Thyroid-stimulating hormone (TSH) levels were higher in patients with thyroid autoimmunity (3.34 μU/ml, range 0.0–615.0 μU/ml) than in control subjects (1.84 μU/ml, range 0.0–149.0 μU/ml) (P < 0.001). Even higher TSH levels were observed in patients with both anti-TPO and anti-TG (4.55 μU/ml, range 0.0–197.0 μU/ml). CONCLUSIONS—Thyroid autoimmunity seems to be particularly common in girls with diabetes during the second decade of life and may be associated with elevated TSH levels, indicating subclinical hypothyroidism.
- 6 June 2002
- Published by Wiley in Diabetic Medicine
- Vol. 19 (6) , 518-521
Predictivity of thyroid autoantibodies for the development of thyroid disorders in children and adolescents with Type 1 diabetes
Aims To investigate the prevalence of thyroid autoantibodies and their significance for the development of thyroid disorders in children and adolescents with Type 1 diabetes.Methods Antibodies to thyroglobulin (anti‐TG) and thyroperoxidase (anti‐TPO) were measured in 216 patients (113 boys; median age 12.9 years (range 1–22 years)) with Type 1 diabetes (diabetes duration 2.5 years (0–14 years)) in a cross‐sectional study. Sixteen patients with significantly elevated anti‐TPO titres were followed longitudinally (6.0 years (4–13 years)) including the measurement of anti‐TPO, anti‐TG, T3, T4, thyroid‐stimulating hormone (TSH) and ultrasound assessment.Results Twenty‐two patients (10.0%) had significantly elevated titres of anti‐TPO, 19 (8.7%) of anti‐TG and 13 (5.9%) of both autoantibodies. Girls had more frequently elevated anti‐TPO antibodies than boys (P < 0.05). Eight of 16 patients (50%) developed thyroid disorders defined by a TSH elevation (≥ 4.5 µU/ml) and/or sonographic thyroid abnormalities during a median time of 3.5 years (2–6 years) after first detection of anti‐TPO positivity. They were characterized by higher levels of anti‐TPO (P = 0.001) and a more frequent coexistence of anti‐TG antibodies (P = 0.002) than those with no development of thyroid disorder even after an observation period of 5.5 years (5–10 years).Conclusions Because 50% of children with diabetes and significant titres of anti‐TPO develop thyroid problems within 3–4 years, examinations of thyroid antibodies should be performed yearly. In cases of significant antibody titres, thyroid function tests and ultrasound assessment are recommended in order to minimize the risk of undiagnosed hypothyroidism in these patients.
- 6 June 2002
- Published by Wiley in Diabetic Medicine
- Vol. 19 (6) , 518-521
Predictivity of thyroid autoantibodies for the development of thyroid disorders in children and adolescents with Type 1 diabetes
Aims To investigate the prevalence of thyroid autoantibodies and their significance for the development of thyroid disorders in children and adolescents with Type 1 diabetes.Methods Antibodies to thyroglobulin (anti‐TG) and thyroperoxidase (anti‐TPO) were measured in 216 patients (113 boys; median age 12.9 years (range 1–22 years)) with Type 1 diabetes (diabetes duration 2.5 years (0–14 years)) in a cross‐sectional study. Sixteen patients with significantly elevated anti‐TPO titres were followed longitudinally (6.0 years (4–13 years)) including the measurement of anti‐TPO, anti‐TG, T3, T4, thyroid‐stimulating hormone (TSH) and ultrasound assessment.Results Twenty‐two patients (10.0%) had significantly elevated titres of anti‐TPO, 19 (8.7%) of anti‐TG and 13 (5.9%) of both autoantibodies. Girls had more frequently elevated anti‐TPO antibodies than boys (P < 0.05). Eight of 16 patients (50%) developed thyroid disorders defined by a TSH elevation (≥ 4.5 µU/ml) and/or sonographic thyroid abnormalities during a median time of 3.5 years (2–6 years) after first detection of anti‐TPO positivity. They were characterized by higher levels of anti‐TPO (P = 0.001) and a more frequent coexistence of anti‐TG antibodies (P = 0.002) than those with no development of thyroid disorder even after an observation period of 5.5 years (5–10 years).Conclusions Because 50% of children with diabetes and significant titres of anti‐TPO develop thyroid problems within 3–4 years, examinations of thyroid antibodies should be performed yearly. In cases of significant antibody titres, thyroid function tests and ultrasound assessment are recommended in order to minimize the risk of undiagnosed hypothyroidism in these patients.
- 1 January 2002
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 15 (1) , 47-52
Age-Specific Levels of Diabetes-Related GAD and IA-2 Antibodies in Healthy Children and Adults
Glutamic acid decarboxylase (GAD) and tyrosine phosphatase IA-2 antibody levels were measured in 375 healthy children and adults and in 187 children with newly diagnosed type 1 diabetes mellitus (DM). GAD antibody levels were determined by radioimmunoassay, and IA-2 antibody levels by immunoprecipitation. Healthy children had higher GAD antibody levels than adults (p < 0.001). The 98th percentile was 1.60 U/ml in children and 1.16 U/ml in adults. IA-2 antibody levels did not differ between these two cohorts. Children with DM had higher GAD and IA-2 antibody levels than healthy children (p <0.001). Based on receiver operating characteristics (ROC) analysis, elevated levels of these antibodies showed high specificity rates (+/- SE) of 0.968 +/- 0.14 to 1.00 +/- 0.00. The sensitivity ranged between 0.439 +/- 0.037 (both antibodies elevated) and 0.850 +/- 0.027 (at least one antibody elevated). These data emphasize the importance of establishing age-specific reference values for DM-related antibodies in the background population before applying them for screening and intervention studies.
- 1 January 2002
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 15 (1) , 47-52
Age-Specific Levels of Diabetes-Related GAD and IA-2 Antibodies in Healthy Children and Adults
Glutamic acid decarboxylase (GAD) and tyrosine phosphatase IA-2 antibody levels were measured in 375 healthy children and adults and in 187 children with newly diagnosed type 1 diabetes mellitus (DM). GAD antibody levels were determined by radioimmunoassay, and IA-2 antibody levels by immunoprecipitation. Healthy children had higher GAD antibody levels than adults (p < 0.001). The 98th percentile was 1.60 U/ml in children and 1.16 U/ml in adults. IA-2 antibody levels did not differ between these two cohorts. Children with DM had higher GAD and IA-2 antibody levels than healthy children (p <0.001). Based on receiver operating characteristics (ROC) analysis, elevated levels of these antibodies showed high specificity rates (+/- SE) of 0.968 +/- 0.14 to 1.00 +/- 0.00. The sensitivity ranged between 0.439 +/- 0.037 (both antibodies elevated) and 0.850 +/- 0.027 (at least one antibody elevated). These data emphasize the importance of establishing age-specific reference values for DM-related antibodies in the background population before applying them for screening and intervention studies.
- 1 June 2000
- Published by Wiley in Diabetic Medicine
- Vol. 17 (6) , 441-444
Autoantibodies to tissue transglutaminase are sensitive serological parameters for detecting silent coeliac disease in patients with Type 1 diabetes mellitus
Summary: Aims To investigate the clinical significance of the determination of IgA antibodies to tissue transglutaminase (tTG) for the detection of silent coeliac disease in patients with Type 1 diabetes mellitus. Methods A total of 520 patients with diabetes (median age 14.2 years, range 1–27) were tested for IgA antibodies to tTG (IgA anti‐tTG, ELISA), endomysium (EmA, indirect immunofluoresence) and gliadin (IgA‐AGA, enzyme immunometric assay) after ruling out IgA deficiency. Results The prevalence of IgA anti‐tTG among patients with diabetes was 4.4% (23 of 520), and that of EmA and IgA‐AGA 3.5% (18 of 520, respectively). The coefficient of agreement between IgA antitTG and EmA was high (Cohen's kappa = 0.87, P < 0.001). Thirteen of the 23 IgA anti‐tTG‐positive patients underwent duodenal biopsy. Coeliac disease was confirmed in nine of 13 patients. One of them was negative for EmA and AGA, but positive for IgA anti‐tTG. Retrospective annual determinations up to 8 years in six IgA anti‐tTG‐positive patients showed both permanent and transient elevations of the serological markers. Conclusions These data show that a positive IgA antibody test to tTG is a more sensitive parameter than EmA for silent coeliac disease in patients with diabetes. Confirmatory small bowel biopsy, however, remains necessary for diagnosis as some patients with positive antibodies may be without histological changes.
- 1 June 2000
- Published by Wiley in Diabetic Medicine
- Vol. 17 (6) , 441-444
Autoantibodies to tissue transglutaminase are sensitive serological parameters for detecting silent coeliac disease in patients with Type 1 diabetes mellitus
Summary: Aims To investigate the clinical significance of the determination of IgA antibodies to tissue transglutaminase (tTG) for the detection of silent coeliac disease in patients with Type 1 diabetes mellitus. Methods A total of 520 patients with diabetes (median age 14.2 years, range 1–27) were tested for IgA antibodies to tTG (IgA anti‐tTG, ELISA), endomysium (EmA, indirect immunofluoresence) and gliadin (IgA‐AGA, enzyme immunometric assay) after ruling out IgA deficiency. Results The prevalence of IgA anti‐tTG among patients with diabetes was 4.4% (23 of 520), and that of EmA and IgA‐AGA 3.5% (18 of 520, respectively). The coefficient of agreement between IgA antitTG and EmA was high (Cohen's kappa = 0.87, P < 0.001). Thirteen of the 23 IgA anti‐tTG‐positive patients underwent duodenal biopsy. Coeliac disease was confirmed in nine of 13 patients. One of them was negative for EmA and AGA, but positive for IgA anti‐tTG. Retrospective annual determinations up to 8 years in six IgA anti‐tTG‐positive patients showed both permanent and transient elevations of the serological markers. Conclusions These data show that a positive IgA antibody test to tTG is a more sensitive parameter than EmA for silent coeliac disease in patients with diabetes. Confirmatory small bowel biopsy, however, remains necessary for diagnosis as some patients with positive antibodies may be without histological changes.